Clinical Trials
Avanir reports safety update from ongoing study of Neurodex
Published in Medical Letter on the CDC and FDA, July 9th, 2006
Avanir Pharmaceuticals (AVNR) announced the submission of additional data from its ongoing open label study assessing safety in chronic exposure to Neurodex, an investigational new drug that is the subject of a new drug application (NDA). Neurodex is currently in priority review at the U.S. Food and Drug Administration (FDA) for the treatment of involuntary emotional expression disorder (IEED), and in phase III clinical development as a potential treatment for painful diabetic neuropathy.
The results of the 120 day safety update were consistent with prior data from the Neurodex IEED trials and were submitted to the FDA. Additional results from this study will continue...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
More Articles from Medical Letter on the CDC and FDA
- Food-Borne Illness
Salmonella Heidelberg outbreaks in U.S. traced to poultry and eggs - Food-Borne Illness
Aging of cheese made from unpasteurized milk does not eliminate Escherichia coli O157:H7 - HIV/AIDS Diagnosis
HIV RNA testing improves diagnosis of HIV infection in high-risk patients - Hepatitis E Virus
Locally acquired hepatitis E virus infection in Texas reported - Sexual & Reproductive Health
High-risk behaviors linked to Viagra use among men who have sex with men - Acute Myelogenous Leukemia
CuraGen and TopoTarget announce NCI-sponsored Phase II clinical trial with PXD101 for AML - More from this issue of Medical Letter on the CDC and FDA
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
